Rituximab is frequently used off-label as a treatment for relapsing-remitting multiple sclerosis (MS) because it induces the depletion of circulating B-cell and T-cell lymphocytes and targets CD20 protein in B cells that are responsible for the production of antibodies.
Rituximab is frequently used off-label as a treatment for relapsing-remitting multiple sclerosis (MS) because it induces the depletion of circulating B-cell and T-cell lymphocytes and targets CD20 protein in B cells that are responsible for the production of antibodies.
A French study1 recently presented at the European Committee for Treatment and Research in Multiple Sclerosis investigated the impact of rituximab on regulatory T-cells (Treg), which play a role in immune modulation and have been identified as promoting oligodendrocyte differentiation and remyelination.
A total of 43 patients with MS, 19 with relapsing-remitting and 24 with progressive disease, received 1000 mg rituximab intravenously, followed by a maintenance dose of 1000 mg in 6 months.
Researchers recorded circulating lymphocyte kinetics (B CD19/B CD20/B CD27/T CD4/T CD8/Treg/NK cells) before the first infusion (M0) and 6 months later (M6). Secondary outcomes were the annualized relapse rate (ARR), expanded disability status scale (EDSS), and MRI activity.
Mean (SD) EDSS at baseline was 5.2 (1.4) and 5.3 (1.5) at 6 months, respectively. ARR significantly decreased at M6 from a mean 1.18 (1.2) to 0.18 (0.6) (P=.00094). MRI activity was reported in 11% of patients, compared with 56% at baseline. Levels of CD19+ and CD27+ memory B-cell lymphocytes were significantly depleted at M6 (both P <.0001). Although percentages of CD8+ lymphocytes remained unchanged, a significant increase in CD4+ lymphocyte levels was found at M6 [M0: 44.7% (10.8) to M6: 52.6% (8.8); P=.0008].
Among CD4+ T cells, activated Treg percentage remained unchanged. However, quiescent Treg significantly increased (M0: 1.56% [1.36] to M6: 2.3% [2.2]; P=.036). There was no observed change in natural killer and natural killer T-cell populations.
These results suggest that rituximab treatment is associated with an unexpected upregulation of circulating CD4+ lymphocytes and quiescent Treg levels, the latter of which the researchers hypothesize could reflect the reduced conversion of Treg into activated Treg in rituximab responders. However, future trials with a larger cohort and a longer follow-up are needed.
A second study2 presented at the same meeting compared rituximab with fingolimod, dimethyl fumarate, and natalizumab in patients with MS. Most had relapsing-remitting disease. Researchers found the odds of discontinuing treatment at 24 months or less was lower for patients taking rituximab versus fingolimod and dimethyl fumarate. The researchers said that rituximab demonstrated the lowest unadjusted disease activity outcomes of all the treatments, which are considered highly effective therapies.
The study included 182, 271, 342, and 451 patients who initiated rituximab, fingolimod, dimethyl fumarate, and natalizumab, respectively, between January 2010 and October 2013. The primary outcome was the probability of drug discontinuation by the end of year 2. The researchers controlled for age, disease duration, type of MS, gender, and enhancing lesion at baseline.
At 24 months, 46 (25.3%), 93 (34.3%), 161 (47.1%), and 147 (32.6%) patients discontinued rituximab, fingolimod, dimethyl fumarate, and natalizumab, respectively. Fingolimod versus rituximab had an adjusted odds ratio (aOR) of 1.96 (95% CI, 1.23-3.13; P=.005) of discontinuation by 24 months. Dimethyl fumarate versus rituximab had an aOR of 3.32 (95% CI, 2.15-5.13; P <.001). Natalizumab versus rituximab had an aOR of 1.50 (95% CI, 0.99-2.28; P =.109).
The leading cause of discontinuation of rituximab and natalizumab were issues involving insurance (9.9%), and being positive for John Cunningham Virus (12.6%), respectively.
Adverse events were the leading cause for discontinuation of fingolimod (17%) and dimethyl fumarate (24.0%). Fewer rituximab-treated patients (14.8%) experienced disease activity during follow-up compared with fingolimod (34.7%, P <.001), dimethyl fumarate (33.6%, P <.001), and natalizumab (22.2%, P =.037).
References
1. Maillart E, Ungureanu A, Derai D, et al. Impact of rituximab on Treg lymphocytes in MS patients. Presented at the European Committee for the Treatment and Research in Multiple Sclerosis annual meeting, October 10-12, 2018; Berlin, Germany. Abstract P554. https://onlinelibrary.ectrims-congress.eu/ectrims/2018/ectrims-2018/228398/elisabeth.maillart.impact.of.rituximab.on.treg.lymphocytes.in.ms.patients.html?f=media=3*search=rituximab*browseby=8.
2. Vollmer B, Nair K, Sillau S, Corboy J, Vollmer T, Alvarez E. Comparison of rituximab vs fingolimod, dimethyl fumarate and natalizumab in the treatment of multiple sclerosis: two year experience. Presented at the European Committee for the Treatment and Research in Multiple Sclerosis annual meeting, October 10-12, 2018; Berlin, Germany. Abstract P562. https://onlinelibrary.ectrims-congress.eu/ectrims/2018/ectrims-2018/228406/brandi.vollmer.comparison.of.rituximab.vs.fingolimod.dimethyl.fumarate.and.html?f=menu=14*media=3*speaker=546718*browseby=8.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How Vertical Integration Drives Innovation and Access in Biosimilars
December 27th 2024Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while emphasizing the value of collaboration, quality control, and value-based contracts for sustainable health care delivery.
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.